• High-dose melphalan and autologous stem cell transplantation (HDM/ASCT) is widely used in immunoglobulin light chain (AL) amyloidosis, but the benefit is debated mainly because of the high treatment-related mortality (24% in a randomised study comparing HDM/ASCT with oral melphalan/dexamethasone). (lu.se)
  • The results show that consolidation plus maintenance after either bortezomib, melphalan, and prednisone [VMP] or high-dose melphalan, autologous stem-cell transplantation [ASCT] deepens the response and significantly improves the PFS in comparison with maintenance alone," Sonneveld and colleagues wrote. (medpagetoday.com)
  • High-dose melphalan followed by ASCT, as well as maintenance with lenalidomide, remain standard treatment for transplant-eligible patients with newly diagnosed multiple myeloma. (medpagetoday.com)
  • In this study, patients received induction with 3 to 4 cycles of vincristine, cyclophosphamide, and dexamethasone, and mobilization of stem cells was performed, after which patients either underwent therapy with 4 cycles of VMP, or high-dose melphalan and single or double ASCT. (medpagetoday.com)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • Here we present an analysis of SPM incidence and profile the SPM type to determine the impact of autologous stem cell transplantation (ASCT) and lenalidomide exposure in 4358 patients treated on study. (nyu.edu)
  • During the COVID-19 outbreak, planned autologous stem cell transplant (ASCT) for patients may be postponed to a more suitable time. (mpeurope.org)
  • High-dose therapy (usually high-dose melphalan), and the ASCT procedure itself, weaken the immune system and potentially make myeloma and AL amyloidosis patients more susceptible and less able to fight infections like COVID-19. (mpeurope.org)
  • The aim of this study is to evaluate the prognostic impact of myeloid-derived suppressor cells (MDSCs) in multiple myeloma (MM) in the context of autologous stem cell transplantation (ASCT). (biomedcentral.com)
  • Both MDSC phenotypes pre-ASCT but not post-ASCT similarly suppressed in vitro autologous T and natural killer T cell proliferation. (biomedcentral.com)
  • Importantly, pre-ASCT M-MDSCs more strongly inhibited the in vitro cytotoxic effect of melphalan compared with pre-ASCT E-MDSCs. (biomedcentral.com)
  • Finally, blockade of CSF1R substantially recovered the melphalan-induced cytotoxicity reduced by pre-ASCT M-MDSCs. (biomedcentral.com)
  • Our data demonstrate that pre-ASCT M-MDSCs are correlated with poor clinical outcomes after ASCT through reduced cytotoxicity of melphalan. (biomedcentral.com)
  • We propose that targeting CSF1R on these cells may improve the results of ASCT in MM. (biomedcentral.com)
  • Bortezomib-based regimens are a valuable consolidation option, especially for patients who failed excellent response after autologous stem cell transplantation (2A). (haematologica.org)
  • Until the year 2000, the standard therapy for MM was melphalan- or doxorubicin-based regimens with corticosteroids. (biomedcentral.com)
  • 17. Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma. (whocc.org.cn)
  • Conditioning regimens consisted of high-dose melphalan (MEL) with or without total body irradiation (TX1 = 35) and MEL as the first preparative regim. (shengsci.com)
  • These guidelines provide a comprehensive assessment of eligibility criteria, stem cell collection and mobilisation strategies and regimens, risk-adapted melphalan dosing, role for induction and consolidation therapies, specific supportive care management, long-term outcome with respect to survival, haematologic response and relapse and organ responses following stem cell transplantation. (medthority.com)
  • These findings demonstrate that bortezomib is safe and has a potential role in conditioning regimens in combination with BuMel for patients with transplantation-eligible MM. (elsevierpure.com)
  • Cao XX, Wang T, Liu YH, Zhou DB, Li J. Successful treatment of scleromyxedema with melphalan and dexamethasone followed by thalidomide maintenance therapy. (medscape.com)
  • New data from the phase III study (MM-020/IFM 07-01) of lenalidomide-low-dose dexamethasone reached its primary end point of a statistically significant improvement in progression-free survival as compared to melphalan-prednisone-thalidomide and provides further evidence for the efficacy of lenalidomide-low-dose dexamethasone in transplant-ineligible patients (2B). (haematologica.org)
  • This tumor-induced diffuse bone loss compounds the treatment-induced bone loss from frequent use of high-dose glucocorticoid medications (typically dexamethasone), leading to severe osteoporosis. (snmjournals.org)
  • Bone Marrow Transplantation (2000) 26, 877-880. (nature.com)
  • Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. (nature.com)
  • Multiple myeloma (MM) is a cancer of terminally differentiated plasma B cells that originates in the hematopoietic bone marrow and accounts for 15%-20% of all hematologic malignancies ( 1 , 2 ). (snmjournals.org)
  • Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of transformed monoclonal plasma cells in the bone marrow (BM) [ 1 ]. (biomedcentral.com)
  • Diagnosis typically requires demonstration of M-protein (sometimes present in urine and not serum but rarely absent entirely) and/or light-chain proteinuria, and excessive plasma cells in the bone marrow. (msdmanuals.com)
  • Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion. (mims.com)
  • It occurs in 10-15% of patients with full-blown multiple myeloma but can also be seen when the affected patient has less than 10% bone marrow plasma cells, the quantity typically required to make a diagnosis of myeloma. (askhematologist.com)
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
  • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • Figure 8‐2 Acute leukemia can be considered "naturally metastatic" in that the neoplasm arises within the white blood cell progenitors produced in the bone marrow. (pocketdentistry.com)
  • Dr. George Mathé explored the transplantation of bone marrow cells from healthy donors to treat patients accidentally irradiated at high dose, expanding the possibilities of this life-saving technique (Mathé et al. (revistadehematologia.org.mx)
  • In April 1960, Dr. Álvaro Gómez-Leal, presented during the first meeting of the Agrupación Mexicana para el Estudio de la Hematología, A.C., data on a transplant of allogeneic stem cells in a patient with acute leukemia done in Monterrey, Mexico: the patient received high-dose chemotherapy followed by stem cells from the bone marrow of his brother, improving and obtaining remission for months but relapsing and subsequently died. (revistadehematologia.org.mx)
  • Multiple myeloma (MM) is an incurable plasma cell malignancy of the bone marrow. (snmjournals.org)
  • Multiple myeloma (MM) is an incurable malignancy characterized by clonal proliferation of plasma cells in the bone marrow microenvironment. (snmjournals.org)
  • There is no end organ damage in MGUS or in a more progressed condition called smoldering MM. Accordingly, MGUS and smoldering MM are usually not treated, but there are investigational chemoprevention trials attempting to halt the progression to symptomatic MM. In smoldering MM, bone marrow biopsy shows a 10%-60% diffuse infiltration of plasma cells, and the infiltration is less than 10% in MGUS. (snmjournals.org)
  • Although MM can arise de novo, it usually progresses in a stepwise fashion from MGUS or smoldering MM. If marrow infiltration with plasma cells exceeds 60%, or if end organ damage is present, the patient is diagnosed with active MM ( 1 , 2 ). (snmjournals.org)
  • Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. (medscape.com)
  • Bone marrow aspirate demonstrating plasma cells of multiple myeloma. (medscape.com)
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines also recommend the use of serum free light chain assay and plasma cell fluorescence in situ hybridization (FISH) on bone marrow: del 13, del 17p13, t(4;14), t(11;14), t(14;16), t(14;20), 1q21 amplification, 1p deletion as part of the initial diagnostic workup. (medscape.com)
  • usually normocytic and normochromic related both to the replacement of normal marrow by expanding tumour cells and to the inhibition of haematopoiesis by factors made by the tumour. (sunzek.com)
  • Based on the presence of at least 10% clonal bone marrow plasma cells and monoclonal protein in serum or urine. (sunzek.com)
  • In patients with true nonsecretory myeloma, the diagnosis is based on 30% monoclonal bone marrow plasma cells or a biopsy proven plasmcytoma. (sunzek.com)
  • Biology of Blood and Marrow Transplantation , 25 (7), 1312-1319. (elsevierpure.com)
  • In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. (nature.com)
  • While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. (biomedcentral.com)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • However, melphalan efficacy is variable in the clinical population, especially in relapsed and refractory MM, and is also implicated in various toxicities, including severe mucositis and myelosuppression. (snmjournals.org)
  • There is an unmet need to develop novel therapies for refractory/relapsed MM. In the past few years, chimeric antigen receptor (CAR)-modified T cell therapy for MM has shown promising efficacy in preclinical and clinical studies. (biomedcentral.com)
  • Antibody- and T-cell-based approaches to targeting of B-cell maturation antigen have shown efficacy. (msdmanuals.com)
  • Immunotherapy utilizing T cell immunity has become a new treatment to eliminate cancer cells. (biomedcentral.com)
  • Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel immunotherapy which modifies T cells with CAR, an artificial fusion protein that incorporates an extracellular antigen recognition domain, a transmembrane domain, and an intracellular domain including costimulation and signaling components [ 4 , 5 ]. (biomedcentral.com)
  • The GAC contributed to multiple high impact publications, including supporting the generation of RNA-Seq and ATAC-Seq data to elucidate tumor- specific characteristics that underlie variability of immune cell infiltration and response to immunotherapy using a mouse pancreatic cancer model (Li et al. (grantome.com)
  • He's a member of ASH and ASCO and he's a popular lecture/speaker on an Anti-CD19 CAR T Cell immunotherapy for multiple myeloma. (healthtree.org)
  • Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. (shengsci.com)
  • Adding thalidomide to a standard regimen of high-dose chemotherapy in patients with the cancer multiple myeloma improved complete responses but did not give any advantage in five-year survival, according to a study published in the New England Journal of Medicine (March 9). (pharmatimes.com)
  • The study of 668 patients with newly-diagnosed multiple myeloma compared treatment with two courses of Celgene's Alkeran (melphalan) to the combination of Alkeran and Celgene's Thalomid brand of thalidomide alongside autologous stem cell transplantation. (pharmatimes.com)
  • Thalidomide, originally used as a treatment for morning sickness, was taken off the market in the 1960s because women who took it during pregnancy had a much higher rate of severe birth defects. (pharmatimes.com)
  • Conclusions: When incorporated into high-dose therapy for myeloma, thalidomide increased the frequency of complete responses and extended event-free survival at the expense of added adverse effects without improving overall survival. (elsevierpure.com)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • In the last decade, the availability of autologous stem cell transplantation and combination therapies consisting of immunomodulatory drugs, proteasome inhibitors, and other chemotherapeutics has improved median 5-y survival from 34.6% in 2004 to 49.6% in 2013 ( 3 , 4 ). (snmjournals.org)
  • 2008. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. . (myelomacenter.org)
  • Methods: Between October 1998 and February 2004, 668 patients with newly diagnosed multiple myeloma received two cycles of intensive melphalan-based chemotherapy, each supported by autologous hematopoietic stem-cell transplantation. (elsevierpure.com)
  • Novel-agent-based induction and up-front autologous stem cell transplantation in medically fit patients remains the standard of care (1A). (haematologica.org)
  • Patients treated with isatuximab-RVd (six cycles) had lower numbers of collected stem cells compared to those receiving RVd (six cycles) induction (8.8 × 10 6 /kg bw versus 9.7 × 10 6 /kg bw, p = 0.801), without experiencing significant delays in LP or increased numbers of LP sessions in a multivariable logistic regression analysis. (biomedcentral.com)
  • This study demonstrates that stem cell collection is feasible after prolonged induction with isatuximab-RVd without collection failures and might be further explored as induction therapy. (biomedcentral.com)
  • PBSC mobilization should be performed after induction therapy to ensure collection of a sufficient number of cells. (biomedcentral.com)
  • The high‐dose induction chemotherapy regimen that will be used to treat this patient is profoundly myelosuppressive, and typically causes severe ulcerative oral mucositis for at least two weeks duration. (pocketdentistry.com)
  • The SPM incidence was higher in patients who received lenalidomide at induction and maintenance (double exposure), when compared to those treated with lenalidomide at one time point (single exposure). (nyu.edu)
  • Equivocal end-of-therapy imaging findings do not predict a higher risk of local relapse after definitive radiotherapy in pediatric Ewing sarcoma and rhabdomyosarcoma. (ucdenver.edu)
  • Previous studies have shown that children with acute myeloid leukemia (AML) who developed mixed chimerism (MC) were at high risk for relapse after allogeneic stem-cell transplantation (allo-SCT). (shengsci.com)
  • Melphalan-prednisone-lenalidomide with lenalidomide maintenance increases progression-free survival, but overall survival data are needed. (haematologica.org)
  • Thalomid was also associated with higher event-free survival at five years (56% versus 43%), but the overall survival rate was no different at 65% a piece. (pharmatimes.com)
  • Because the toxicity of melphalan is dose-related and survival with AL may be age-related, patient age and the extent of organ involvement can provide a basis for patient stratification. (elsevierpure.com)
  • Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
  • In recent years, with a combination of autologous stem-cell transplantation and modern chemotherapy, the 10-y survival of patients presenting at an age less than 60 y is approximately 30% ( 1 , 2 ). (snmjournals.org)
  • Background: High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. (elsevierpure.com)
  • elicits antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. (medscape.com)
  • Management of HEV characteristics and treatments of patients with hematologic infection in the context of allogeneic stem cell transplanta- malignancies before or within the 6 months after the diag- tion (SCT) has been a matter of controversy ( 5 , 6 ). (cdc.gov)
  • For post-transplantation best response, an 83% rate of VGPR or better (68% CR) was observed. (elsevierpure.com)
  • BCMA, a member of the tumor necrosis factor (TNF) superfamily, is exclusively expressed in a subpopulation of B cells, normal plasma cells, and malignant plasma cells. (biomedcentral.com)
  • Lesions are caused by bone replacement by expanding plasmacytomas or by cytokines that are secreted by malignant plasma cells that activate osteoclasts and suppress osteoblasts, leading to bone loss. (merckmanuals.com)
  • The five-year study revealed that the complete response rate among the Thalomid group, defined as the disappearance of malignant cells in the blood, was 62%, significantly higher than the 43% seen in the control group. (pharmatimes.com)
  • Multiple Myeloma is a malignant proliferation of plasma cells derived from a single clone. (sunzek.com)
  • Two main advantages of BCMA as an antigen for CAR-T therapy are the potential reduction of on-target/off-tumor toxicity and the lack of antigen-dependent reduction in CAR-T cell expansion [ 16 ]. (biomedcentral.com)
  • High-dose chemoradiotherapy is the major cause of organ toxicity. (slideshare.net)
  • In elderly patients or patients in whom autologous transplantation is not possible in the future, melphalan and prednisone (MP) therapy is preferred because of its ease of administration and low toxicity. (medscape.com)
  • The patients were evaluated based on PBSC mobilization and collection parameters, including overall collection results, CD34 + cell levels in peripheral blood, leukapheresis (LP) delays, overall number of LP sessions, and the rate of rescue mobilization with plerixafor. (biomedcentral.com)
  • However, during stem cell mobilization and -collection, no study-specific therapeutic intervention was performed. (biomedcentral.com)
  • In this review, we briefly discuss recent advances in AL, such as the free light-chain assay and the role of immunoglobulin light-chain variable region germline genes in the disease, and then we discuss the current status of SCT for AL with emphases on patient selection, approaches to stem cell mobilization, and peri-SCT management. (elsevierpure.com)
  • Melphalan therapy induced a statistically significant reduction in lesion avidity and uptake for both 18 F-FDG and 18 F-FDOPA. (snmjournals.org)
  • 18 F-FDOPA PET/CT complemented 18 F-FDG PET/CT in imaging melphalan therapy response in preclinical extramedullary MM. 18 F-FDOPA uptake was linked to LAT1 expression and melphalan response, with longitudinal imaging suggesting stabilization of LAT1 levels and melphalan tumor cytotoxicity. (snmjournals.org)
  • Future work will explore additional MM cell lines with heterogeneous LAT1 expression and response to melphalan therapy. (snmjournals.org)
  • Thus, stratification of melphalan-responsive patients in the MM patient population is critical for reducing therapy-induced toxicities. (snmjournals.org)
  • Furthermore, the toxicities of CAR-T cell therapy are manageable. (biomedcentral.com)
  • Several antigens have been used as targets for CAR-T cell therapy against MM, including B cell maturation antigen (BCMA), CD19, CD138, signaling lymphocytic activation molecule 7 (SLAM7), and immunoglobulin light chains. (biomedcentral.com)
  • Radiation Therapy for Young Children Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant for Primary Brain Tumors. (ucdenver.edu)
  • 15. Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent. (whocc.org.cn)
  • Dr. Garfall of the University of Pennsylvania describes how CAR T cell therapy works and how the first target of CD19 was used in combination with autologous stem cell transplant. (healthtree.org)
  • Used for patients who had already relapsed after transplant in a clinical trial of 10 patients, he shares the mixed results to date with one del 17 patient that never achieved complete response (CR) in the first transplant, achieving it in the second transplant with the addition of CAR T cell therapy. (healthtree.org)
  • Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. (shengsci.com)
  • The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
  • Recently, cell therapy has improved remission in patients with relapsed or refractory MM. While avoiding vaccines that contain live viruses, COVID-19 vaccination is highly recommended for patients with MM. Here, we aim to rapidly review the literature and point out the current clinical management of MM. (actascientific.com)
  • All patients with symptomatic disease should undergo risk stratification to classify patients for International Staging System stage (level of evidence: 1A) and for cytogenetically defined high- versus standard-risk groups (2B). (haematologica.org)
  • The L-type amino acid transporter 1 (LAT1) is a key mediator in uptake and intracellular accumulation of melphalan and correlates with melphalan sensitivity and response in MM and other cancers ( 8 - 10 ). (snmjournals.org)
  • Achievement of a complete response on 18 F-FDG PET before stem-cell transplantation correlates with a superior outcome. (snmjournals.org)
  • Transplant Cell Ther. (bu.edu)
  • About half of people with light chain deposition disease also have a plasma cell dyscrasia, a spectrum of diseases that includes multiple myeloma, Waldenström's macroglobulinemia, and the monoclonal gammopathy of undetermined significance premalignant stages of these two diseases. (wikipedia.org)
  • Multiple myeloma (MM) is a debilitating neoplasm of terminally differentiated plasma B cells that resulted in over 13,000 deaths in 2017 alone. (snmjournals.org)
  • Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study. (zhaw.ch)
  • RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect. (dukecancerinstitute.org)
  • Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (msdmanuals.com)
  • Training CAR T cells to seek and destroy specific proteins on the surface of multiple myeloma cells (and the cells themselves) are an exciting new area of study. (healthtree.org)
  • you have been participating in this CAR T-cell research for quite sometime even before myeloma. (healthtree.org)
  • Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. (shengsci.com)
  • A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. (myelomacenter.org)
  • 2017. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. . (myelomacenter.org)
  • 2014. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. . (myelomacenter.org)
  • 2013. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. . (myelomacenter.org)
  • High-Cutoff Hemodialysis in Myeloma Cast Nephropathy. (myelomacenter.org)
  • The bone lesions of myeloma are caused by the proliferation of tumour cells and the activation of the osteoclasts that destroy the bone. (sunzek.com)
  • Enhancement of human erythroid progenitor cell growth by media conditioned by a human t-lymphocyte line. (shengsci.com)
  • The proteasome pathway is an enzyme complex existing in all cells, which degrades ubiquitinated proteins that control the cell cycle and cellular processes and maintains cellular homeostasis. (medscape.com)
  • Combination therapies involving melphalan, a small-molecule DNA alkylating agent, are commonly prescribed to patients with relapsed or refractory MM, necessitating the stratification of responding patients to minimize toxicities and improve quality of life. (snmjournals.org)
  • One of the main therapies used for MM is the small-molecule alkylating agent melphalan ( 5 - 7 ). (snmjournals.org)
  • Light chain deposition disease (LCDD) is a rare blood cell disease which is characterized by deposition of fragments of infection-fighting immunoglobulins, called light chains (LCs), in the body. (wikipedia.org)
  • The combination treatment was also associated with higher rates of blood clots and damage to the nerves. (pharmatimes.com)
  • At least 6.5 x 10(8) [corrected] mononuclear cells/kg patient weight were collected from the peripheral blood of each patient, cyropreserved, and returned intravenously following CBV administration. (shengsci.com)
  • Recent studies have shown that soluble factors elaborated by human T lymphocytes enhance erythroid burst formation by human peripheral blood null cells. (shengsci.com)
  • CASE REPORT: We report a case of light chain deposition disease associated with plasma cell dyscrasia presenting as sicca syndrome with salivary glands hypertrophy and polyneuropathy successfully treated by high dose melphalan and autologous blood stem transplantation. (hal.science)
  • We discuss such a risk-adapted approach to melphalan dosing in detail and conclude with a brief overview of current research using SCT to treat patients with AL. (elsevierpure.com)
  • For this purpose, we retrospectively used planning computed tomography (CT) data from 10 patients treated with HT with a total dose of 8 Gy (n = 5) or 12 Gy (n = 5) for treatment planning for VMAT with a small field size (36 × 22 cm). (bvsalud.org)
  • The majority of cases were diagnosed in TE patients treated with lenalidomide maintenance (n = 25, incidence 2.8%), suggesting a possible link with melphalan. (nyu.edu)
  • Later, meta-analysis suggested the link to be secondary to lenalidomide in combination with melphalan. (nyu.edu)
  • Non-melanoma skin cancer incidence was highest in patients receiving lenalidomide maintenance, particularly in TNE patients, where squamous cell carcinoma and basal cell carcinoma were diagnosed in 5.5% and 2.6% of patients, respectively. (nyu.edu)
  • The incidence of most solid tumour types was higher in lenalidomide maintenance patients. (nyu.edu)
  • Загальні відомості про плазмоклітинні захворювання Plasma cell disorders are a diverse group of disorders of unknown etiology characterized by Disproportionate proliferation of a single clone of B cells Presence of a structurally and electrophoretically. (msdmanuals.com)
  • MDSCs are characterized by myeloid origin, immature state, and most importantly by their potent ability to suppress different aspects of immune responses, especially T cell proliferation and cytokine production [ 7 ]. (biomedcentral.com)
  • The presence of inflammatory cytokines after high-dose chemotherapy leads to proliferation and activation of MDSCs originating from autologous hematopoietic progenitors at the time of engraftment. (biomedcentral.com)
  • The identification of patients with high symptom burden management should focus on the assessment of demographic and clinical characteristics, in addition to functional status. (bmj.com)
  • Currently, allogeneic stem cell transplantation may be considered for young patients with high-risk disease and preferably in the context of a clinical trial (2B). (haematologica.org)
  • however, the disease is commonly associated with plasma cell dyscrasia. (medscape.com)
  • Early mortality is high, but with a decreasing trend over time. (lu.se)
  • Except for 3 patients with transplantation-related mortality due to sepsis, other adverse events were manageable. (elsevierpure.com)